Infective endocarditis: 10-year experience in a non-cardiovascular center

Endocarditis infecciosa: experiencia de 10 años en un centro no cardiovascular

Arturo M. Ruiz-Beltran¹, Clemente Barron-Magdaleno², Sandra M. Ruiz-Beltran³, Jose D. Sánchez-Villa¹, Consuelo Orihuela-Sandoval², Jorge Oseguera-Mogue², and Gerardo Payro-Ramírez²*

¹Department of Internal Medicine; ²Department of Cardiology, Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City; ³Department of Anesthesiology, Hospital General Dr. Manuel Gea González, Mexico City, Mexico

Abstract

Background and objective: Infective endocarditis (IE) is an infection with a poor prognosis, and an associated in-hospital mortality of at least 25%. Optimal therapy of IE requires long-term effective antibiotic therapy and valve surgery in many cases. The aim of this study was to review the demographics, bacteriology, and outcomes of patients with IE admitted to a tertiary referral center in Mexico City, over a 10-year period. Methods: Retrospective cohort study of patients admitted at Instituto Nacional Salvador Zubiran with a new diagnosis of IE over a 10-year period, from January 2009 to January 2019. Patients who met the definition for definitive diagnosis of infective endocarditis according to the modified Duke criteria were included in the study. Results: There were 62 patients (50.85 ± 17.46 years, 40.3% females) with IE. The culprit microorganism was identified in all cases, with Staphylococcus aureus being the most frequently found (34%). Valve surgery was performed in 58.1%, while 41.9% only received medical treatment. The mortality rate was 25.8% at 30 days and 41.9% at 12 months. Comparing the surgical and medical treatment groups, we found that 50% and 36% in each group, respectively, had died within 12 months of admission. Conclusions: Our center has a high prevalence of health care-associated endocarditis, mostly related to the presence of intravascular access devices. Most of the patients had a surgical indication. Patients with type 2 diabetes mellitus and decreased right ventricular systolic function had an increased mortality rate at 12 months.

Keywords: Infective endocarditis. Health care-associated endocarditis. Heart valve disease.

Resumen

Antecedentes y objetivo: La endocarditis infecciosa (EI) es una infección de mal pronóstico, con una mortalidad intrahospitalaria que va del 15-20%. La terapia óptima requiere antibioterapia efectiva por tiempo prolongado y cirugía valvular en algunos casos. El objetivo de este estudio fue revisar la epidemiología y desenlaces de pacientes con EI en un centro de referencia en la Ciudad de México. Métodos: Cohorte retrospectiva de pacientes admitidos al Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán con diagnóstico de EI en un periodo de 10 años, de enero de 2009 a enero de 2019. Se incluyeron a pacientes que cumplieran la definición de diagnóstico definitivo de endocarditis infecciosa de acuerdo a los criterios modificados de Duke. Resultados: Se incluyeron a 62 pacientes (50.85 ± 17.46 años, 40.3% mujeres). Todos los
Introduction

Infective endocarditis (IE) is an infection of the cardiac endothelium that advances rapidly and can present with fever, sepsis, and systemic complications. Historically, it was diagnosed on the basis of classic findings of active valvulitis, embolic manifestations, and vascular immunologic phenomena, together with positive blood cultures. However, nowadays epidemiology has shifted towards health care-associated IE, which does not present with all the classic findings. Furthermore, this epidemiological change has led to an increase in the prevalence of *Staphylococcus aureus*.

Despite advances in medical knowledge, technology, and antimicrobial therapy, the prognosis for IE continues to be poor, with an in-hospital mortality of at least 25%.

Optimal IE therapy requires long-term effective antibiotic therapy and valve surgery in some cases. According to the European College of Cardiology (ESC) guidelines, surgical indications include heart failure secondary to valve dysfunction, uncontrolled infection, and prevention of septic embolisms. Heart failure is the most frequent complication of IE and represents the most common indication for surgery.

The purpose of our study was to review the demographics, bacteriology, and outcomes of patients with IE admitted to a tertiary referral center in Mexico City, over a 10-year period.

Methods

We conducted a retrospective cohort study of patients admitted at Instituto Nacional Salvador Zubiran with a new diagnosis of IE over a 10-year period, from January 2009 to January 2019. Patients who met the definition for definitive diagnosis of infective endocarditis according to the modified Duke criteria were included in the study. Both written and electronic patient records were reviewed. A total of 145 records were reviewed, of which only 62 met the inclusion criteria.

Demographic, clinical, and biochemical data recorded at the time of initial assessment were collected. Isolates in blood culture and/or biopsy were recorded. Diagnostic imaging tests were recorded, including the most important echocardiographic data.

For each case, it was evaluated whether they met surgical criteria according to the 2015 ESC guidelines. If so, the indication and the level of recommendation for each of these indications were included in the study.

Finally, the length of stay, antibiotic days, 30-day mortality, 12-month reinfections, 12-month readmissions, and 12-month mortality were recorded.

The cases were categorized as community acquired or health care-associated. Health care-associated endocarditis was defined as IE developing in a patient hospitalized for more than 48 h before onset of signs/symptoms or as IE diagnosed within 48 h of admission in patients with close contact with health services as reflected by any of the following criteria: (1) receipt of intravenous therapy, wound care, or specialized nursing care at home within the 30 days before the onset of IE; (2) attendance at a hospital or hemodialysis clinic or receipt of intravenous chemotherapy within the 30 days before the onset of IE; (3) hospitalization in an acute care hospital for 2 or more days in the 90 days before the onset of IE; or (4) residence in a nursing home or long-term care facility.

For the analysis, patients were divided in two groups: patients with medical treatment only and patients with surgical treatment. Categorical variables were expressed as percentages. Continuous variables were expressed as means ± standard deviation. Groups were compared by performing Chi-square test for the categorical variables and Student’s t-test for the continuous variables. A two-sided p < 0.05 was considered statistically significant. All analyses were performed using the SPSS version 22 (SPSS for Mac; IBM, Chicago, Illinois, USA).
Results

A total of 62 patients were included, of whom 25 were women and 37 were men, with a mean age of 50.85 ± 17.46 years. The baseline characteristics of the patients are presented in Table 1, while the clinical characteristics are presented in Table 2. Forty-four (70.9%) patients had left IE. Of the total of patients, 35 (56.5%) were classified as healthcare-associated IE, the most frequent cause of this being the presence of intravenous access device in 29 (46.8%) of them. Patients with congenital heart defects were not included. Only 5 (8.1%) patients had IE associated with a prosthetic valve.

Within the diagnostic approach, 35 (56.5%) underwent an abdominal CT scan, 24 (38.7%) a head MRI, and 6 (9.7%) underwent a nuclear medicine test. In those who underwent an MRI, a stroke was observed in 14 (22.6%). Meanwhile, 50 (80.6%) patients underwent transthoracic echocardiography and 54 (87.1%) underwent transesophageal echocardiography. The echocardiographic findings at diagnosis are described in Table 3. The most frequently affected valve was the mitral valve (29%) followed by the aortic valve (22.6%) and the mitro-aortic complex (19.4%). Valvular vegetation was found in 59 (95%) of the patients and 7 (11.3%) of them presented non-valvular vegetation. The mean size of the vegetations was 16.5 ± 6.3 mm. Furthermore, an abscess was found in 10 patients (4 valvular and 6 perivalvular).

Blood cultures were requested from all patients and microbiological isolation was found in 57 (91.9%) of the patients. The most frequently isolated bacteria were Staphylococcus aureus (22%), Streptococcus viridans (17.5%), and Enterococcus (12%).

### Table 1. Clinical and demographic data

| Parameter                                      | Values |
|------------------------------------------------|--------|
| Number of patients, n (%)                     | 62 (100) |
| Age, years*                                    | 50.85 ± 17.46 |
| Gender                                         |        |
| Female, n (%)                                  | 25 (40.3) |
| Male, n (%)                                    | 37 (59.7) |
| Type 2 diabetes mellitus, n (%)                | 22 (35.5) |
| Systemic arterial hypertension, n (%)          | 34 (54.8) |
| Liver cirrhosis, n (%)                         | 7 (11.3) |
| Cigarette smoking, n (%)                       | 18 (29) |
| Cancer, n (%)                                  | 13 (21.3) |
| Chronic kidney disease, n (%)                  | 24 (39.3) |
| Dental disease, n (%)                          | 8 (12.9) |
| Hemodialysis, n (%)                            | 23 (37.1) |
| Intravenous drugs use, n (%)                   | 1 (1.6) |
| Surgery in the past 30 days, n (%)             | 11 (17.7) |
| Intravenous access device, n (%)               | 29 (46.8) |
| Pacemaker, n (%)                               | 3 (4.8) |
| Cardiopathy, n (%)                             | 3 (4.8) |
| Heart valve disease, n (%)                     | 15 (24.2) |
| Prosthetic heart valve, n (%)                  | 5 (8.1) |
| Immunosuppression, n (%)                       | 13 (21) |
| Human immunodeficiency virus, n (%)            | 1 (1.6) |

*Data expressed as mean ± standard deviation.

### Table 2. Clinical presentation

| Parameter                                      | Values |
|------------------------------------------------|--------|
| Symptoms at presentation:                     |        |
| Fever, n (%)                                   | 56 (90) |
| Chills, n (%)                                  | 40 (64.5) |
| Diaphoresis, n (%)                             | 11 (17.7) |
| Weight loss, n (%)                             | 19 (30.6) |
| Malaise, n (%)                                 | 53 (85.5) |
| Headache, n (%)                                | 7 (11.3) |
| Arthralgias, n (%)                             | 10 (16.1) |
| Abdominal pain, n (%)                          | 16 (25.8) |
| Dyspnea, n (%)                                 | 11 (17.7) |
| Chest pain, n (%)                              | 2 (3.2) |
| Signs at presentation:                        |        |
| New cardiac murmur, n (%)                     | 36 (58.1) |
| Altered mental status, n (%)                   | 10 (16.1) |
| Focal neurological deficit, n (%)              | 6 (9.7) |
| Petechiae, n (%)                               | 4 (6.5) |
| Splenomegaly, n (%)                            | 22 (35.5) |
| Janeway lesions, n (%)                         | 6 (9.7) |
| Osler nodes, n (%)                             | 0 (0) |
| Roth spots, n (%)                              | 7 (11.3) |
| Complications:                                 |        |
| Heart failure, n (%)                           | 19 (30.6) |
| Septic emboli, n (%)                           | 34 (54.8) |
| Metastatic infection, n (%)                    | 8 (12.9) |
| Glomerulonephritis, n (%)                      | 1 (1.6) |
| Embolic stroke, n (%)                          | 14 (22.6) |
| Laboratory findings:                          |        |
| Hemoglobin, g/dL*                              | 10.13 ± 2.5 |
| Platelets, ×109/dL*                            | 184.05 ± 119.5 |
| Leucocytes, ×109/dL*                           | 12.76 ± 5.96 |
| Creatinine, mg/dL*                             | 3.87 ± 4.11 |
| Bilirubin, mg/dL*                              | 1.33 ± 1.42 |
| ALT, U/dL*                                     | 30.2 ± 39.18 |
| AST, U/dL*                                     | 38.4 ± 35.7 |
| Albumin, g/dL*                                 | 2.75 ± 0.8 |
| C reactive protein, mg/dL*                     | 12.5 ± 6.8 |
| Erythrocyte sedimentation rate, mm/hour*       | 53.3 ± 33.8 |

*Data expressed as mean ± standard deviation.
them, while 15 of heart valve cultures were positive. Two microorganisms were found in 3 patients. Overall, the culprit organism was identified in all patients: *Staphylococcus* in 28/62 (*S. aureus* in 21, *S. epidermidis* in 6, and *Staphylococcus saprophyticus* in 1), *Streptococcus* in 16/62 (*S. galolyticus* in 4, *S. viridans* in 1, *S. mitis* in 2, *S. agalactiae* in 2, *S. sp* in 2, *S. sanguis* in 2, *S. parasanguinis* in 1, *S. pyogenes* in 1, and *Granulicatella adiacens* in 1), *Enterococcus faecalis* in 8/62, Gram-negative bacilli in 3/62 (*E. coli* in 2 and *Acinetobacter baumannii* in 1), fungi in 6/62 (*C. glabrata* in 1, *C. albicans* in 2, *C. parapsilosis* in 2, and *C. tropicalis* in 1), *Corynebacterium jeikeium* in 3/62, and *Lactobacillus* sp. in 1/62.

Regarding treatment, 36 (58.1%) received surgical treatment, while 26 (41.9%) received medical treatment only. In the surgical treatment group, valve replacement was performed in 33 patients, while the remaining 3 patients underwent vegetectomy. The median time between diagnosis and surgery was 5.5 days (IQR 3-12.5). Of the prosthetic valves employed during surgery, 63.6% were mechanical and the remaining 36.4% were biological valves. One of the patients died in the operating room. Only 2 patients in the surgical treatment group required surgical reintervention 30 days after the initial procedure.

The median length of hospital stay was 34 days (IQR 24.5-52.5) and the median length of antibiotic therapy was 42 days (IQR 28-42). In the 30-day follow-up, 16 (25.8%) patients died, the most frequent cause being septic shock. When the medical and surgical treatment groups were compared, it was found that 30.7% (8/26) and 22.2% (8/36) of each group, respectively, had died within 30 days, but this difference was not statistically significant (*p = 0.44*). Regarding the 12-month outcomes, reinfection was found in 5 and rehospitalization in 8, and 26 (41.9%) had died in that period of time. At 12 months, it was found that 13/26 (50%) and 13/36 (36%) of the medical and surgical group, respectively, had died, but this difference was not statistically significant (*p = 0.27*).

The mean left ventricular ejection fraction was 60.2 ± 11.9% and 59.3 ± 6.6% in the group that survived and died at 12 months, respectively. On the other hand, the mean tricuspid annular plane systolic excursion was 23.9 ± 5.15 mm and 20.7 ± 4.34 mm in the group that survived and died at 12 months, respectively, with this difference being statistically significant (*p = 0.026*).

Regarding the comorbidities of the patients, it was found that type 2 diabetes mellitus was associated with a higher mortality at 12 months (*p = 0.01*). When these patients with diabetes mellitus (n = 22) were separated by age, the 12-month mortality rate was 63.6% (7/11) in both those under and above 60 years of age.

When evaluating whether the patients had surgical intervention criteria according to ESC guidelines, it was found that 54 (87%) of them had an indication for surgery. Of these, 28 (51.9%) had an indication with class of recommendation IIb, and 8 (14.8%) with class of recommendation IIa, and 8 (14.8%) with class of recommendation IIb. The most frequent indications were: (1) severe valve dysfunction with vegetation >10 mm in the mitral or aortic valve in 16 (25.8%), (2) severe valve regurgitation with symptoms of heart failure in 15 (24%), (3) vegetation >15 mm in 8 (12.9%), and (4) presence of an abscess in 10 (16%) patients. In those who had a surgical indication and did not undergo surgery, a

| Table 3. Echocardiographic findings | Values |
|--------------------------------------|--------|
| Left ventricle ejection fraction, % * | 59.8 ± 9.7 |
| Left ventricle global longitudinal strain, % * | 18.5 ± 4.3 |
| Pulmonary artery systolic pressure, mmHg * | 44.7 ± 19.8 |
| Tricuspid annular plane systolic excursion, mm * | 22.3 ± 4.9 |
| Affected valve, n (%) | 18 (29.5) |
| Mitral | 14 (23) |
| Aortic | 9 (14.8) |
| Tricuspid | 12 (19.7) |
| Pulmonary | 1 (1.6) |
| Aortic and mitral | 1 (1.6) |
| Right atrium involvement, n (%) | 5 (8.2) |
| Valvular vegetation, n (%) | 59 (95) |
| Non-valvular vegetation, n (%) | 7 (11.3) |
| Number of vegetations* | 1.68 ± 1 |
| Maximal vegetation size, mm* | 16.5 ± 6.3 |
| Mobile vegetation, n (%) | 37 (59.7) |
| Papillary muscle rupture, n (%) | 5 (8.1) |
| Abscess, n (%) | 10 (16) |
| Valvar | 4 (6.5) |
| Perivalvar | 6 (9.7) |
| Valvar perforation, n (%) | 8 (12.9) |
| Valvar dysfunction, n (%) | 53 (85) |
| Severe regurgitation | 35 (58) |

*Data expressed as mean ± standard deviation.
12-month mortality of 52% (10/19) was found against a 37% (13/35) mortality in those who had an indication and did undergo surgery, but this difference did not turn out to be statistically significant (p = 0.4).

Regarding the recommended time for surgery, 49 (91%) had a recommendation to perform the surgery urgently (in the next 7 days) and 5 (9%) to perform it electively (in 1-2 weeks). Only 20 (37%) underwent surgery in the time recommended by the ESC. In those who did not undergo surgery in the recommended time, the mortality rate at 12 months was 27.8% (15/54), against a mortality rate of 14.3% (8/54) in those who did undergo surgery in the indicated time, but this difference was not statistically significant (p = 0.76).

Discussion

We report the results of a retrospective cohort, in which we evaluated the clinical characteristics and outcomes of adults with IE in a third-level non-cardiovascular center.

This series found a predominance of Gram-positive microorganisms (90% of cases), with *S. aureus* being the most frequently isolated microorganism (34%), of which 33.3% were methicillin-resistant. This is similar to what was reported in the study of the International Collaboration on Endocarditis (ICE). However, we found 6 (9.6%) cases of yeast, 3 (5%) of gram-negative bacilli, 3 (4.8%) of *Corynebacterium jeikeium*, and 1 (1.6%) case of *Lactobacillus*, which differs from what was published in other series. The ICE study, for example, reported a yeast frequency of 1.6% globally and 1.1% in South American countries. It is possible that the isolates found in our series respond to the large proportion of patients with health care-associated IE (56.5%) and the large proportion of patients with intravascular accesses (46.8%).

Even with diagnostic and therapeutic advances, IE is associated with a poor prognosis, with an in-hospital mortality rate that ranges from 15 to 25% and a 12-month mortality of approximately 40%. However, Botelho-Nevers et al. demonstrated a reduction in mortality with the implementation of a medical and surgical treatment protocol, achieving a 12-month mortality of 8.2%. Our center has a high prevalence of health care-associated IE, and this was associated with a low presentation of the classic clinical characteristics of IE; the index of suspicion should be high, particularly in patients who have intravascular access devices.

Patients with IE that had a former diagnosis of type 2 diabetes mellitus and those with decreased right ventricular systolic function at the time of diagnosis had an increased mortality rate at 12 months. Most of the patients had surgical criteria at the time of diagnosis, but not all had surgery, nor was this intervention performed in the recommended time in all. Therefore, we believe that institutional protocols should be implemented in order to promote valve surgery in
patients with surgical indication and to ensure that this is performed within the recommended time by international guidelines.

Funding
This research has not received any specific grant from agencies in the public, commercial, or non-profit sectors.

Conflicts of interest
None.

Ethical disclosures
Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.
Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.
Right to privacy and informed consent. The authors declare that no patient data appear in this article.

References
1. Wang A, Gaca JG, Chu VH. Management considerations in infective endocarditis: a review. JAMA. 2018;320:72-83.
2. Jung B, Duval X. Infective endocarditis: innovations in the management of an old disease. Nat Rev Cardiol. 2019;16:623-635.
3. Federspiel JJ, Steams SC, Peppercorn AF, Chu VH, Fowler VG Jr. Increasing US rates of endocarditis with Staphylococcus aureus: 1999-2008. Arch Intern Med. 2012;172:383-5.
4. Bin Abdulhak AA, Baddour LM, Erwin PJ, Hoen B, Chu VH, Mensah GA, et al. Global and regional burden of infective endocarditis, 1990-2010: a systematic review of the literature. Glob Heart. 2014;9:131-43.
5. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC guidelines for the management of infective endocarditis: The task force for the management of infective endocarditis of the European society of cardiology (ESC). Endorsed by: European association for cardio-thoracic surgery (EACTS), the European association of nuclear medicine (EANM). Eur Heart J. 2015;36:3075-128.
6. Tornos P, Iung B, Permanyer-Miralda G, Baron G, Delahaye F, Gohlke-Bärwolf C, et al. Infective endocarditis in Europe: lessons from the Euro heart survey. Heart. 2005;91:571-5.
7. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG Jr., Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the international collaboration on endocarditis-prospective cohort study. Arch Intern Med. 2009;169:463-73.
8. Shah AS, McAllister DA, Gallacher P, Astengo F, Pérez JA, Hall J, et al. Incidence, microbiology, and outcomes in patients hospitalized with infective endocarditis. Circulation. 2020;141:2067-77.
9. Cabell CH, Jollis JG, Peterson GE, Corey GR, Anderson DJ, Sexton DJ, et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med. 2002;162:30-4.
10. Nissen H, Nielsen PF, Frederiksen M, Helleberg C, Nielsen JS. Native valve infective endocarditis in the general population: a 10-year survey of the clinical picture during the 1980s. Eur Heart J. 1992;13:372-7.
11. Benn M, Hageløksjäer LH, Tweé M. Infective endocarditis, 1984 through 1993: a clinical and microbiological survey. J Intern Med. 1997;242:15-22.
12. Botelho-Nevers E, Thuny F, Casalta JP, Richet H, Gouriet F, Collart F, et al. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med. 2009;169:1290-4.
13. Leone S, Ravasio V, Durante-Mangoni E, Crapis M, Carosi G, Scotton PG, et al. Epidemiology, characteristics, and outcome of infective endocarditis in Italy: the Italian study on endocarditis. Infection. 2012;40:527-35.
14. Nadji G, Rusinaru D, Rémiadé JP, Jeu A, Sorel C, Tribouly C. Heart failure in left-sided native valve infective endocarditis: characteristics, prognosis, and results of surgical treatment. Eur J Heart Fail. 2009;11:688-75.
15. Olmos C, Vilacosta I, Fernández C, López J, Sarría C, Ferrera C, et al. Contemporary epidemiology and prognosis of septic shock in infective endocarditis. Eur Heart J. 2013;34:1999-2006.
16. Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J. 2019;40:3222-32.
17. Habib G, Badano L, Tribouly C, Vilacosta I, Zamorano JL, Galderisi M, et al. Recommendations for the practice of echocardiography in infective endocarditis. Eur J Echocardiogr. 2010;11:202-19.